Recent discussions on X about Hims & Hers Health (HIMS) have been buzzing with interest, particularly around the company's innovative telehealth model and its rapid revenue growth. Many users have ...

Men suffering from hair loss and thinning have praised a treatment brand whose plans cost as little as £1 per day for a month's supply. While many resort to wearing hats to hide hair loss, Hims Hair ...

Hims & Hers Health, Inc. (HIMS) closed at $28.89 in the latest trading session, marking a -5.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 1.16% for the ...

We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans, driving 50% Y/Y revenue growth.

Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a consumer-first, ...

It has been about a month since the last earnings report for Hims & Hers Health, Inc. (HIMS). Shares have lost about 15.1% in that time frame, underperforming the S&P 500. Will the recent negative ...

Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we ...

In Q3 2025, Hims & Hers Health reported revenue of around US$600 million, nearly 50% year-over-year growth, alongside higher ARPU and free cash flow of US$79 million, even as gross margins faced ...

One of the more popular ideas floating around on Wall Street, Hims & Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong ...

Hims & Hers Health's ads have been getting attention from the Trump administration. President Donald Trump's administration on Tuesday rolled out a memorandum aimed at limiting direct-to-consumer ...

President Donald Trump’s administration on Tuesday rolled out a memorandum aimed at limiting direct-to-consumer advertising for pharmaceuticals, with one senior administration official indicating that ...